<DOC>
	<DOCNO>NCT00100906</DOCNO>
	<brief_summary>RATIONALE : Tretinoin may help cell involve body 's immune response work well . Interleukin-2 may stimulate white blood cell kill kidney cancer cell . Giving tretinoin together interleukin-2 may kill tumor cell . PURPOSE : This randomized phase II trial study well give three different dos tretinoin together interleukin-2 work treat patient stage IV kidney cancer .</brief_summary>
	<brief_title>Sequential ATRA Then IL-2 Modulation Dendritic Cells Treatment Metastatic Renal Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine ratio dendritic cell ( DC ) circulate immature cell ( ImC ) treatment 3 different dos tretinoin patient stage IV renal cell cancer . - Assess vitro immune response assay tetanus toxoid influenza virus peptide treatment tretinoin interleukin-2 patient . Secondary - Determine frequency treatment-related side effect patient . - Determine clinical objective response progression-free survival patient treat regimen . - Correlate DC : ImC ratio clinical objective response patient treat regimen . - Correlate extent change DC : ImC ratio tretinoin dose tretinoin blood level patient . OUTLINE : This randomize , open-label study . Specimens stratify accord patient prognostic factor , tumor bulk , extent dendritic cell circulate immature cell ratio derangement . Patients randomize 1 3 tretinoin dos . Patients follow 2 year . PROJECTED ACCRUAL : A total 27-36 patient ( 9-12 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell cancer Stage IV disease Histology clear cell component Metastatic OR incompletely resect disease Nonmeasurable disease allow Underwent complete partial nephrectomy 90 day ago No unresected primary cancer No 2 follow adverse factor : Hemoglobin &lt; 10.0 g/dL Corrected calcium &gt; upper limit normal ( ULN ) Lactic dehydrogenase &gt; 1.5 time ULN Eastern Cooperative Oncology Group ( ECOG ) performance status 2 Brain metastasis allow provided 90 day clinical radiologic stability end active treatment PATIENT CHARACTERISTICS : Age Over 18 Performance status See Disease Characteristics ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic See Disease Characteristics Serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 3 time normal Bilirubin &lt; 2 time normal Renal See Disease Characteristics Creatinine clearance &gt; 40 mL/min Cardiovascular None follow cardiovascular condition within past year : Uncontrolled hypertension Myocardial infarction Unstable angina New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Class IIIV peripheral vascular disease within past year Other clinically significant cardiovascular disease Immunologic No history immunodeficiency disease No HIV infection No ongoing serious infection Other Not pregnant nursing Negative pregnancy test Fertile patient must use two method effective contraception 1 month ( woman ) 6 month ( men ) study treatment Other prior malignancy allow provided evidence active disease No medical contraindication tretinoin interleukin2 No serious nonhealing wound , ulcer , bone fracture PRIOR CONCURRENT THERAPY : Biologic therapy At least 60 day since prior immunotherapy Chemotherapy At least 60 day since prior cytotoxic chemotherapy Endocrine therapy See Radiotherapy No prior corticosteroid &gt; physiologic replacement dos &gt; 3 day within past 90 day Concurrent tamoxifen , toremifene , megestrol , gonadotropinreleasing hormone agonist allow Concurrent inhale steroid allow Radiotherapy More 7 day since prior externalbeam radiotherapy No steroid requirement radiotherapy Surgery See Disease Characteristics At least 30 day since prior debulking surgery Other Prior adjuvant therapy resect , synchronous stage IV disease allow Prior adjuvant therapy allow Study therapy use adjuvant therapy completely resect late ( &gt; 1 year identification ) solitary site disease metastasis nonmetastatic disease No prior participation clinical study At least 60 day since prior anticancer drug Concurrent seizure medication allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>